ERBB2 and breast carcinoma: For instance, anthracycline-based adjuvant trastuzumab regimen for a 49-year-old women with early-stage HER2-positive breast cancer had an ICER of $39,892/QALY [10], adjuvant trastuzumab chemotherapy for women with HER2-positive breast cancer had an ICER of $26,417/QALY [15], and a more recent study by Hedden et al. reported that the adjuvant trastuzumab chemotherapy for women with HER2-positive breast cancer has an ICER of $13,095/QALY [20].